<code id='E55CD60BC6'></code><style id='E55CD60BC6'></style>
    • <acronym id='E55CD60BC6'></acronym>
      <center id='E55CD60BC6'><center id='E55CD60BC6'><tfoot id='E55CD60BC6'></tfoot></center><abbr id='E55CD60BC6'><dir id='E55CD60BC6'><tfoot id='E55CD60BC6'></tfoot><noframes id='E55CD60BC6'>

    • <optgroup id='E55CD60BC6'><strike id='E55CD60BC6'><sup id='E55CD60BC6'></sup></strike><code id='E55CD60BC6'></code></optgroup>
        1. <b id='E55CD60BC6'><label id='E55CD60BC6'><select id='E55CD60BC6'><dt id='E55CD60BC6'><span id='E55CD60BC6'></span></dt></select></label></b><u id='E55CD60BC6'></u>
          <i id='E55CD60BC6'><strike id='E55CD60BC6'><tt id='E55CD60BC6'><pre id='E55CD60BC6'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:comprehensive    Page View:29813
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more
          FDA rejects Alnylam's heart disease treatment over insufficient data
          FDA rejects Alnylam's heart disease treatment over insufficient data

          KristofferTripplaar/SipaUSA/APTheFoodandDrugAdministrationrejectedanAlnylamPharmaceuticals’therapyfo

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          What to expect at HLTH 2023, the health care industry conference

          AdobeSTAT’sMohanaRavindranathandAnnalisaMerelliwillbeatHLTHinLasVegasandwillbewritingadailyemaildisp